Condition: Cancer Harboring BRAF Alterations · HGG · LGG · Sponsor: Fore Biotherapeutics
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E-mutated solid tumors, including anaplastic thyroid, ovarian, cholangiocarcinoma or other rare cancers.
This description comes directly from the study's public registry record.
Jessica Rine · 610-442-4517 · jessica.rine@fore.bio
Geri Bardelli · 978-835-2310 · geraldine.bardelli@fore.bio
Always discuss trial participation with your own doctor first.
| Precision NextGen Oncology & Research Center | Beverly Hills, California, United States | Recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| University of California Los Angeles Rheumatology | Westwood, Los Angeles, California, United States | Recruiting |
| Norwalk Hospital | Norwalk, Connecticut, United States | Recruiting |
| University of Miami Hospital and Clinics | Miami, Florida, United States | Recruiting |
| The John Hopkins Hospital | Baltimore, Maryland, United States | Recruiting |
| Maryland Oncology Hematology- Columbia | Rockville, Maryland, United States | Recruiting |
| Tufts Medical Center | Boston, Massachusetts, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Not Yet Recruiting |
| St. Luke's Hospital | Duluth, Minnesota, United States | Recruiting |
| Mosaic Life Care at Saint Joseph - Medical Center | Saint Joseph, Missouri, United States | Recruiting |
+ 58 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05503797